EUCTR2016-000048-32-DEActive, not recruitingPhase 1
Evaluation of the Therapeutic Effects of Testosterone on Pain Perception in case of Chronic Pain Disorder
RWTH Aachen University/CTC-A0 sites60 target enrollmentStarted: October 10, 2017Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Diagnosis according to ICD-10 F45.40 and / or F45.41
- •2. Age: 18-64 years
- •3. Serum testosterone levels men: <3 µg / l. Women: <0.06 µg/l
- •4. Patients in both groups should be asigned as outpatient (in the pain policlinic at the University Hospital Aachen) or inpatient (in the clinic of psychiatry, psychotherapy and psychosomatics at the RWTH Aachen) for at least 8 weeks presumably.
- •5. Full-aged patients who are mentally and physically able to understand the meaning and scope of the study and to follow the study staff´s instructions
- •6. Signed written informed consent before study participation
- •7. For women: Regular (about yearly) outpatient gynecological examinations. Last cervical smear should be maximum one and a half year ago.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. In women:
- •Breast cancer or other gynaecological tumors in medical history
- •Pregnant and / or breast-feeding women. Women of childbearing potential should be protected by an adequate contraception
- •2. In men:
- •Prostate tumors, chronic prostatitis
- •History of malignant prostate disease in the family, possible untreated sleep apnea, hematocrit above 50%.
- •3. Lack of capacity to consent in the study
- •4. Dementia
- •5. Schizophrenia
- •6. A study participation could pose an unacceptable risk at the judgement of the pincipal investigator due to a pre-existing or concomitant disease or due to the general health state of the patient
- •7. There is a life expectancy of less than six months
- •8. There is a current or pre-existing medical disease or treatment that might influence the evaluation of the study
- •9. The patient has received a study drug in another study within the last 30 days
- •10. Simultaneous participation in another clinical intervention study
- •11. Expected missing compliance
- •12. Alcohol or drug abuse
- •13. The patient is placed in an institution due to governmental or judicial authorities.
- •14. Patients who are in a dependent relationship or employment relationship with the sponsor, investigator or his deputy
- •15. Kidney dysfunction or essential cardiac or hepatic pre-existing conditions
Investigators
Similar Trials
Recruiting
Phase 4
Study of effects of testosterone replacement therapy in hypogonadal men with type 2 diabetes mellitusCTRI/2019/09/021175Dr Ronak Gandhi
Active, not recruiting
Not Applicable
EFFECT OF TESTOSTERON THERAPY ON LOW URINARY TRACTmetabolic syndrome and BPH patients who will undergo simple prostatectomyMedDRA version: 14.1Level: LLTClassification code 10004447Term: Benign prostatic hypertrophySystem Organ Class: 100000004872EUCTR2012-003494-26-ITAZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
Recruiting
Not Applicable
Result of testosterone (name of drug)in liver diseaseCTRI/2019/08/021000Institute of Liver and Biliary Sciences
Completed
Phase 3
Effect of Testosterone Therapy Combined with Very Low Caloric Diet on Weight Loss and Weight Maintenance in Obese Men: A Randomized Controlled TrialObesityACTRN12613000613707niversity of Melbourne100
Recruiting
Phase 3
Testosterone therapy for the treatment of nonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseACTRN12619000701123Austin Health120